Free Trial

David Lebovitz Analyst Performance

Analyst at Citigroup

David Lebovitz is a stock analyst at Citigroup in the medical sector, covering 18 publicly traded companies. Over the past year, David Lebovitz has issued 6 stock ratings, including buy and hold recommendations. While full access to David Lebovitz's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights David Lebovitz's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
51 Last 7 Years
Buy Recommendations
46.00% 23 Buy Ratings
Companies Covered
18 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy46.0%23 ratings
Hold50.0%25 ratings
Sell4.0%2 ratings

Out of 50 total stock ratings issued by David Lebovitz at Citigroup, the majority (50.0%) have been Hold recommendations, followed by 46.0% Buy and 4.0% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
18 companies

David Lebovitz, an analyst at Citigroup, currently covers 18 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
18 companies
100.0%

David Lebovitz of Citigroup specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
7 companies
38.9%
MED - DRUGS
5 companies
27.8%
PHARMACEUTICAL PREPARATIONS
3 companies
16.7%
MEDICAL INFO SYS
1 company
5.6%
MED PRODUCTS
1 company
5.6%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC
1 company
5.6%

David Lebovitz's Ratings History at Citigroup

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
9/2/2025Boost Price Target$450.26$583.00Buy
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
7/11/2025Boost Price Target$315.85$404.00Buy
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
5/2/2025Lower Price Target$62.03$78.00Neutral
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
3/21/2025Boost Price Target$280.77$351.00Buy
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
2/27/2025Boost Price Target$340.91$469.00Buy
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
2/20/2025Boost Price Target$68.80$82.00Neutral